abemaciclib + fulvestrant + nivolumab

This is a combination regimen of three drugs: - **Abemaciclib** is an orally administered small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression in cancer cells. - **Fulvestrant** is a selective estrogen receptor degrader (SERD) that binds to and accelerates the degradation of the estrogen receptor (ER), inhibiting ER signaling in hormone receptor-positive cancers. - **Nivolumab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed death-1 (PD-1) on T cells. By blocking PD-1 interaction with its ligands PD-L1 and PD-L2, it enhances anti-tumor immune responses. The combination has been studied primarily for hormone receptor-positive/HER2-negative metastatic breast cancer. The NEWFLAME phase II trial evaluated this triplet therapy in patients who had progressed on prior endocrine therapy. While the regimen showed anti-tumor activity, it was associated with severe and prolonged immune-related adverse events due to enhanced proinflammatory cytokine production and suppression of regulatory T cell proliferation[1][3].

Other names

abemaciclib + fulvestrant + nivolumab